Participated · Seed · Aug 2026

Apollo Atomics focuses on shrinking and mass-manufacturing the steam generator—the largest component in many nuclear plants—by using a compact metal block with needle-thin channels to transfer heat more efficiently. Its design, based on MIT research, enabled the company to build a reactor it says is roughly 40-times smaller than ones using conventional steam generators and to assemble systems in a factory rather than on site. Apollo has built a 40-kilowatt demonstration reactor at MIT and plans to offer reactor sizes from about 10 megawatts-electric up to 300 megawatts. The company projects it can build a 300 MW plant in under 24 months and estimates the reactor will cost four to five times less to produce than existing designs. Apollo targets a levelized cost of electricity near 3 cents per kilowatt-hour and aims for commercial deployment in 2028. It participated in Y Combinator’s Spring 2026 batch.

Participated · Series A · May 2026

GridCARE develops the Energize platform, which uses physics-based AI models to evaluate grid conditions—congestion, outages, weather, and demand fluctuations—in real time to locate underutilized power capacity. The company positions this approach as a way to shorten interconnection timelines for large data centers and AI facilities from years to months by unlocking existing grid capacity. GridCARE reports active projects across more than a dozen markets representing over 2 gigawatts of prospective AI compute capacity and cites a Portland General Electric collaboration that identified a pathway to unlock more than 400 megawatts with 80 megawatts expected online in 2026. Co-founder and CTO Ram Rajagopal is a Stanford professor on leave, and the company emphasizes working collaboratively with utilities. GridCARE frames the market opportunity around a “Time-to-Energize Crisis,” arguing power availability is a growing bottleneck for AI expansion. Financially, the company recently raised a $64 million Series A in an oversubscribed round that materially increased its valuation versus a round less than a year earlier.

Participated · Series A · May 2026

Pumpkinseed is building the deSIPHR platform to enable de-novo protein sequencing, with the goal of reading proteins directly at the resolution of single amino acids. The company says it aims to manufacture billions of sensors across a silicon wafer to scale access to protein-level biological data. Pumpkinseed presented a team of founders and technical leads in its announcement and plans to grow headcount following the Series A. The startup frames its technology as unlocking biology’s functional layer by enabling direct protein reading rather than inferring function from DNA. The company secured $20M in Series A financing to advance the platform and accelerate hiring and development efforts. No revenue or user metrics were disclosed in the announcement.

Participated · Series C · Jan 2026

Deepgram operates a speech and voice AI platform positioned as infrastructure for developers and enterprises rather than a consumer app. Its platform powers over 200,000 developers and 1,400 organizations, and has processed more than 50,000 years of audio, transcribing over a trillion words. The company has seen rapid APAC growth, with a 96% year‑on‑year increase in API requests and presence in more than 20 APAC markets covering multiple regional languages and dialects. Deepgram plans to open an Asia‑Pacific headquarters in Singapore and expand local sales, support, and low‑latency inference infrastructure to better serve regulated industries and reduce latency. The firm has emphasized low‑latency inference and localized language expertise as key differentiators against large cloud providers and other speech specialists.

Participated · Seed · Oct 2025

Adaptyx Biosciences is building a wearable sensing platform that extends continuous monitoring beyond glucose, capturing small molecules, electrolytes, hormones, drugs, and proteins in real time. The system pairs its molecular data streams with AI-driven analytics to detect health trends early and prompt timely interventions. Initial application areas include heart-failure management, endocrine and fertility care, critical-care drug dosing, and personalized wellness. The company holds an exclusive license to IP generated over more than a decade of research at Stanford University and the Chan Zuckerberg Biohub. Current efforts focus on expanding the molecular switch pipeline, progressing clinical trials for the first indication, and scaling engineering, data-science, and clinical teams. Founded in 2022 and based in Menlo Park, California, Adaptyx’s technology remains investigational and has not yet entered commercial sales. To date, the company has secured $23 million in total funding, including the latest seed round.